Sgi-1776
| Title | Journal |
|---|---|
| Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies. | Journal of medicinal chemistry 20151112 |
| Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors. | ACS medicinal chemistry letters 20131212 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. | Blood 20121025 |
| Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy. | Journal of medicinal chemistry 20121011 |
| Targeting PIM kinase activity significantly augments the efficacy of cytarabine. | British journal of haematology 20120101 |
| The Pim kinases: new targets for drug development. | Current drug targets 20111201 |
| PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. | Oncotarget 20111201 |
| Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. | British journal of cancer 20111108 |
| Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. | Blood 20110721 |
| Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. | Blood 20091105 |
| Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. | Molecular cancer therapeutics 20091001 |